Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Papulopustular Rosacea
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
38
States / cities
Yuma, Arizona • Fort Smith, Arkansas • Long Beach, California + 31 more
Conditions
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Interventions
Apremilast
Drug
Lead sponsor
Julian M. Mackay-Wiggan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Moderate to Severe Papulopustular Rosacea
Interventions
BPX-04 1% minocycline topical gel, BPX-04 2% minocycline topical gel, BPX-04 vehicle topical gel
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Withdrawn Phase 2 Interventional

Deucravacitinib Rosacea

NCT06532136
Conditions
Papulopustular Rosacea
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Papulopustular Rosacea
Interventions
Secukinumab
Drug
Lead sponsor
Anne Chang
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Redwood City, California
Completed Phase 3 Interventional Results available

Clinical Endpoint Study of Ivermectin 1% Cream

NCT02840461
Conditions
Moderate to Severe Papulopustular Rosacea
Interventions
Ivermectin Cream, 1%, Placebo/Vehicle cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Conditions
Papulopustular Rosacea
Interventions
FMX103 1.5%
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
79
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 72 more